# Confirmatory Study of Topical HyBryte™ vs. Placebo for the Treatment of CTCL

> **NCT06470451** · PHASE3 · RECRUITING · sponsor: **Soligenix** · enrollment: 80 (estimated)

## Conditions studied

- CTCL/ Mycosis Fungoides
- CTCL
- Mycosis Fungoides
- Cutaneous T Cell Lymphoma

## Interventions

- **DRUG:** Hypericin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06470451
- **Lead sponsor:** Soligenix
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-01-07
- **Primary completion:** 2026-07
- **Final completion:** 2026-10
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2026-04-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06470451

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06470451, "Confirmatory Study of Topical HyBryte™ vs. Placebo for the Treatment of CTCL". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT06470451. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*